Relationship between dysplasia, p53 protein accumulation, DNA ploidy, and Glut1 overexpression in Barrett metaplasia

Scandinavian Journal of Gastroenterology

Volumn 35, Issue 2, 2000, Pages 131-137

  Younes, M ^a,b,c   Lechago, J ^a,b   Chakraborty, S ^a,b   Ostrowski, M ^a,b   Bridges, M ^a,b   Meriano, F ^a,b   Solcher, D ^a,b   Barroso, A ^a,b   Whitman, D ^a,b   Schwartz, J ^a,b   Johnson, C ^a,b   Schmulen, A C ^a,b   Verm, R ^a,b   Balsaver, A ^a,b   Carlson, N ^a,b   Ertant, A ^a,b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b Diagnostic Clinic of Houston   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Adenocarcinoma; Barrett esophagus; Cancer; Dysplasia; Esophagus; Image analysis; Immunohistochemistry; Progression

Indexed keywords

DNA; PROTEIN P53;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; DYSPLASIA; ESOPHAGUS BIOPSY; ESOPHAGUS CANCER; ESOPHAGUS DISEASE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PLOIDY; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0034001599     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655200750024281     Document Type: Article

References (53)

1. 1. Phillips RW, Wong RK. Barrett's esophagus. Natural history, incidence, etiology, and complications. Gastroenterol Clin North Am 1991;20:791-16.
2. 2. Falk GW, Richter JE. Reflux disease and Barrett's esophagus. Endoscopy 1996;28:13-21.
3. 3. Haggilt RC, Tryzelaar J, Ellis FH, Colcher H. Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am J Clin Pathol 1978;70:1-5.
4. 4. Skinner DB, Walther BC, Riddell RH, Schmidt H, lascone C, DeMeester TR. Barrett's esophagus. Comparison of benign and malignant cases. Ann Surg 1983;198:554-65.
5. 5. Naef AP, Savary M, Ozzello L. Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas. J Thorac Cardiovas Surg 1975;70:826-35.
6. 6. Young JL Jr, Percy CL, Asire AJ, Berg JW, Cusano MW, Gloeckler LA, et al. Cancer incidence and mortality in the United States, 1973-77. Natl Cancer Inst Monogr 1981;57:1-187.
7. 7. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-9.
8. 8. Blot WJ, Devessa SS, Fraumeni JF Jr. Continuing climb in rates of esophageal adenocarcinoma: an update [letter]. JAMA 1993; 270:1320.
9. 9. Streitz JM Jr, Ellis FR Jr, Gibb SP, Balogh K, Watkins E Jr. Adenocarcinoma in Barrett's esophagus. A clinicopathologic study of 65 cases. Ann Surg 1991;213:122-5.
10. 10. Paraf F, Flejou JF, Pignon JP, Fekete F, Potet F. Surgical pathology of adenocarcinoma arising in Barrett's esophagus. Analysis of 67 cases. Am J Surg Pathol 1995;19:183-91.
11. 11. Peters JH, Clark GW, Ireland AP, Chandrasoma P, Smyrk TC, DeMeester TR. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994;108:813-21.
12. 12. Vansandick JW, Vanlanschot JJB, Kuiken BW, Tytgat GNJ, Offerhaus GJA, Obertop H. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998;43:216-22.
13. 13. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991; 32:1441-6.
14. 14. Reid BJ, Weinstein WM, Lewin KJ, Haggitt RC, VanDeventer G, DenBesten L, et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology 1988;94:81-90.
15. 15. Reid BJ, Haggitt RC, Ruhin CE, Roth G, Surawicz, CM, Van Belle G, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988;19:166-78.
16. 16. Tytgat GN. Does endoscopic surveillance in esophageal columnar metaplasia (Barrett's esophagus) have any real value? Endoscopy 1995;27:19-26.
17. 17. Achkar E, Carey W. The cost of surveillance for adenocarcinoma complicating Barrett's esophagus. Am J Gastroenterol 1988;83:291-4.
18. 18. Streitz, JM, Ellis FH, Tilden RL, Erickson RV. Endoscopic surveillance of Barretts esophagus-a cost-effectiveness comparison with mammographic surveillance for breast cancer. Am J Gastroenterol 1998;93:911-5.
19. 19. Isobe M, Emanuel BS, Givol D, Oren M, Croce CM. Localization of a gene for human p53 tumor antigen to band 17p13. Nature 1986;320:84-5.
20. 20. Hinds PW, Finlay CA, Quartin RS, Baker SJ, Fearon ER, Vogelstein B, et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the 'hot spot' mutant phenotypes. Cell Growth Differ 1990;1:571-80.
21. 21. Younes M, Lebovitz RM, Lechago LV, Lechago J. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 1993;105:1637-42.
22. 22. Younes M, Ertan A, Lechago LV, Somoano JR, Lechago J. p53 Protein accumulation is a specific marker of malignant potential in Barrett's metaplasia. Dig Dis Sci 1997;42:697-701.
23. 23. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102:1212-9.
24. 24. Isselbacher KJ. Sugar and amino acid transport by cells in culture-differences between normal and malignant cells. N Engl J Med 1972;286:929-33.
25. 25. Holm E, Hagmuller E, Staedt U, Schlicksieser G, Gunther H-J, Leweling H, et al. Substrate balances across colonie carcinoma in humans. Cancer Res 1995;55:1373-8.
26. 26. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987;235:1492-5.
27. 27. Rollins BJ, Morrison ED, Usher P, Flier JS. Platelet-derived growth factor regulates glucose transporter expression. J Biol Chem 1988;263:16523-6.
28. 28. Hiraki Y, Rosen OM, Birnbaum MJ. Growth factors rapidly induce expression of the glucose transporter gene. J Biol Chem 1988;263:13655-62.
29. 29. Mischoulon D, Rana B, Kotliar N, Pilch PF, Bucher NL, Farmer SR. Differential regulation of glucose transporter 1 and 2 mRNA expression by epidermal growth factor and transforming growth factor-beta in rat hepatocytes. J Cell Physiol 1992;153:288-96.
30. 30. Merrall NW, Plevin R, Gould GW. Growth factors, mitogens, oncogenes and the regulation of glucose transport. Cell Sign 1993;5:667-75.
31. 31. Yamamoto T, Seino Y, Fukumoto H, Koh G, Yano H, Inagaki N, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990;170:223-30.
32. 32. Mellanen P, Minn H, Grenman R, Harkonen P. Expression of glucose transporters in head-and-neck tumors. Int J Cancer 1994;56:622-9.
33. 33. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993;72:2979-85.
34. 34. Guenther BM, Erick MP, Maria MB. Glucose transporter proteins in human insulinomas. Ann Intern Med 1994;121: 109-12.
35. 35. Nagase Y, Takata K, Modyama N, Aso Y, Murakami T, Hirano H. Immunohistochemical localization of glucose transporters in human renal cell carcinoma. J Urol 1995;153:798-801.
36. 36. Younes M, Brown RW, Mody DR, Fernandez L, Laucirica R. GLUTI expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res 1995;15:2895-8.
37. 37. Younes M, Lechago LV, Lechago J. Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Clin Cancer Res 1996;2:1151-4.
38. 38. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PC. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997;80: 1046-51.
39. 39. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 1996;56:1164-7.
40. 40. Younes M, Ertan A, Lechago LV, et al. Human erythrocyte glucose transporter (Glut1) is immunohistochemically detected as a late event during malignant progression in Barrett's metaplasia. Cancer Epidemiol Biom Preven 1997;6:303-5.
41. 41. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994;25:982-3.
42. 42. Pindur A, Chakraborty S, Welch DG, Wheeler TM. DNA ploidy measurements in prostate cancer: differences between image analysis and flow cytometry and clinical implications. Prostate 1994;25:189-98.
43. 43. Biddleston LR, Barham CP, Wilkinson SP, Barr H, Shepherd NA. The histopathology of treated Barretts esophagussquamous reepithelialization after acid suppression and laser and photodynamic therapy. Am J Surg Pathol 1998;22:239-45.
44. 44. Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE. Squamous islands in Barretts esophagus-what lies underneath. Am J Gastroentcrol 1998;93:332-5.
45. 45. Reid BJ, Haggitt RC, Rubin CE, Rabinovitch PS. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 1987;93:1-11.
46. 46. James PD, Atkinson M. Value of DNA image cytometry in the prediction of malignant change in Barrett's oesophagus. Gut 1989;30:899-905.
47. 47. Menke-Pluymers MB, Mulder AH, Hop WC, van Blankenstein M, Tilanus HW. Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus. The Rotterdam Oesophageal Tumour Study Group. Gut 1994;35:1348-51.
48. 48. Fennerty MB, Sampliner RE, Way D, Riddell R, Steinbronn K, Garewal HS. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. Gastroenterology 1989;97:815-20.
49. 49. Shankey TV, Rabinovitch PS, Bagwell B, Bauer KD, Duque RE, Hedley DW, et al. Guidelines for implementation of clinical DNA cytometry. Cytometry 1993;14:472-7.
50. 50. Blount PL, Galipeau PC, Sanchez CA, Neshat K, Levine DS, Yin J, et al. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res 1994; 54:2292-5.
51. 51. Neshat K, Sanchez CA, Galipeau PC, Blount PL, Levine DS, Joslyn G, et al. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 1994;106:1589-95.
52. 52. Welscher GJ, Hinder RA, Bagchi D, Hinder PR, Bagchi M, Perdikis G, et al. Reflux esophagitis in humans is mediated by oxygen-derived free radicals. Am J Surg 1995;170:552-6.
53. 53. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1422-55.